Doctors Note Logo

Published on: 9/14/2026

Does Farxiga interact badly with metformin or insulin after 65?

Farxiga (dapagliflozin) does not have a harmful drug-drug interaction with metformin, and the two are often prescribed together, but combining Farxiga with insulin or insulin-stimulating drugs raises the risk of low blood sugar, so insulin doses may need to be lowered. Adults over 65 also face a higher chance of dehydration, low blood pressure, dizziness, urinary or genital infections, and reduced kidney function, which is why kidney labs and hydration matter more with age. Rare but serious risks such as ketoacidosis with near-normal glucose can occur, especially during illness, fasting, or surgery. Several factors, including your kidney function, other medications, and symptoms to watch for, change the answer for each person, so see below to understand more before adjusting anything.

If you are noticing dizziness, unusual thirst, frequent urination, shakiness, nausea, or signs of infection while on these medications, a free, instant, online symptom check can help you sort out what may be driving your symptoms and how urgently you should act, giving you clear, personalized next steps and better questions to bring to your doctor.

Last reviewed for medical accuracy: 09/13/2026

answer background

Explanation

Understanding Farxiga, Metformin and Insulin in Older Adults

As we age, managing type 2 diabetes often means combining medications such as Farxiga (dapagliflozin), metformin and/or insulin. It’s natural to ask whether these medicines interact badly, especially after age 65. Below is an evidence-based look at how Farxiga works with metformin and insulin, what to watch for, and practical tips to stay safe and in control.


1. How Farxiga Works

  • Drug class: Farxiga is in the SGLT2 inhibitor family.
  • Mechanism: It lowers blood sugar by blocking glucose reabsorption in the kidneys, causing excess sugar to be expelled in urine.
  • Benefits beyond sugar control: Studies have shown Farxiga can reduce risk of heart failure hospitalization and slow progression of kidney disease.

2. Why Combine with Metformin or Insulin?

  • Metformin
    • First-line therapy for type 2 diabetes.
    • Works by decreasing liver glucose output and improving insulin sensitivity.
  • Insulin
    • Replaces or supplements the body’s own insulin.
    • Essential when oral meds alone don’t achieve target blood sugar.
  • Combination goals
    • Better blood sugar control.
    • Lower doses of insulin or other drugs.
    • Potential for weight management benefits.

3. Are There Direct Drug–Drug Interactions?

Current clinical data and prescribing information show:

  • No major pharmacokinetic interactions
    • Farxiga does not significantly alter how metformin or insulin are absorbed, distributed, metabolized or excreted.
  • Complementary modes of action
    • Because each drug works differently, they can be safely combined when dosed appropriately.

That said, combining these medications requires attention to additive effects rather than classic “bad interactions.”


4. Key Safety Considerations After Age 65

  1. Hypoglycemia Risk

    • Farxiga alone rarely causes low blood sugar.
    • When added to insulin, it can increase hypoglycemia risk.
    • Metformin itself doesn’t usually cause low sugar, but multi-drug regimens might.
    • Tip: Monitor blood sugar more frequently after starting or adjusting doses.
  2. Volume Depletion & Blood Pressure

    • SGLT2 inhibitors encourage fluid loss (more trips to the bathroom).
    • Older adults may already have lower blood pressure and reduced thirst response.
    • Signs to watch: dizziness when standing, lightheadedness, rapid heartbeat.
    • Tip: Stay hydrated, and have your healthcare provider check your blood pressure regularly.
  3. Kidney Function

    • Both Farxiga and metformin require monitoring of kidney function (eGFR).
    • Farxiga is approved down to an eGFR of 25 mL/min/1.73 m² for heart and kidney benefits, but you’ll need dose adjustments or temporary hold if dehydration or acute illness occurs.
    • Metformin has guidelines limiting use if kidney function drops too low to prevent lactic acidosis.
    • Tip: Ask your provider for routine kidney tests, especially during illness or after starting a new drug.
  4. Genital and Urinary Tract Infections

    • Farxiga can raise the risk of yeast infections (especially in women) and UTIs.
    • Older adults may have a higher baseline risk.
    • Signs: itching, unusual discharge, burning with urination, fever.
    • Tip: Maintain good hygiene and report symptoms early.
  5. Weight Loss and Nutritional Status

    • Farxiga may lead to modest weight loss, which can be beneficial but also concerning if unintentional in frail seniors.
    • Tip: Keep track of weight changes and discuss any unplanned losses with your doctor.

5. Practical Tips for Safe Use

  • Start low, go slow
    • Work with your doctor to initiate Farxiga at the lowest approved dose and adjust gradually.
  • Self-monitoring
    • Use a home glucose meter and record readings before meals, bedtime and if you feel unwell.
  • Stay hydrated
    • Aim for consistent fluid intake unless otherwise instructed.
  • Medication review
    • Bring all your prescription and over-the-counter medications (including supplements) to each appointment.
  • Foot care
    • Good foot hygiene is essential, since diabetic seniors face higher risk of skin issues.
  • Watch for symptoms
    • Track any episodes of dizziness, lightheadedness, or unusual tiredness.

6. When to Contact Your Healthcare Provider

Reach out promptly if you notice:

  • Blood sugar consistently below 70 mg/dL or symptoms of severe hypoglycemia (e.g., confusion, shaking, sweating).
  • Dizziness or fainting upon standing.
  • Signs of a yeast or urinary infection (see above).
  • Sudden drop in kidney function (e.g., reduced urine output, swelling in legs).
  • Any other concerning or rapidly worsening symptoms.

For general concerns or mild symptoms, you might consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to get personalized guidance before or after seeing your healthcare team:
https://ubiehealth.com/


7. Balancing Risks and Benefits

  • Benefits
    • Improved blood sugar control
    • Potential heart and kidney protection
    • Modest weight loss
  • Risks
    • Higher chance of dehydration and low blood pressure
    • Additional monitoring needs
    • Small increase in infection risk

For most adults over 65, the benefits of adding Farxiga to metformin and/or insulin outweigh the risks—provided there’s close follow-up and attention to side effects.


8. Final Thoughts

Farxiga does not have a classic harmful interaction with metformin or insulin. Instead, the focus is on:

  • Monitoring for additive effects (low blood sugar, dehydration).
  • Regular checks of kidney function and blood pressure.
  • Proactive symptom management.

Managing type 2 diabetes after 65 is a team effort between you and your healthcare providers. Always report new or worsening symptoms, and never hesitate to ask questions about your medications.

If you experience life-threatening or serious symptoms—such as loss of consciousness, severe dizziness, chest pain or difficulty breathing—seek emergency care or contact your doctor immediately. For less urgent concerns, a quick consult with your care team can keep your treatment on track and safe.

Speak to your doctor before making any changes to your diabetes medications. Your healthcare provider knows your personal health history best and can tailor the plan that’s right for you.

(References)

  • * Johnston R, Uthman O, Cummins E, Clar C, Royle P, Colquitt J, Tan BK, Clegg A, Shantikumar S, Court R, O'Hare JP, McGrane D, Holt T, Waugh N. Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. Health Technol Assess. 2017 Jan;21(2):1-218. doi: 10.3310/hta21020. PMID: 28105986; PMCID: PMC5292646.

  • * Dhillon S. Dapagliflozin: A Review in Type 2 Diabetes. Drugs. 2019 Jul;79(10):1135-1146. doi: 10.1007/s40265-019-01148-3. PMID: 31236801; PMCID: PMC6879440.

  • * Comparison chart: SGLT2 inhibitors. Med Lett Drugs Ther. 2020 Nov 16;62(1611):e2-e4. Epub 2020 Nov 16. PMID: 33429417.

  • * Elkind-Hirsch KE, Chappell N, Seidemann E, Storment J, Bellanger D. Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2021 Sep 27;106(10):3019-3033. doi: 10.1210/clinem/dgab408. PMID: 34097062.

  • * Drugs for type 2 diabetes. Med Lett Drugs Ther. 2022 Nov 14;64(1663):177-184. PMID: 36384763.

  • * Sahay RK, Giri R, Shembalkar JV, Gupta SK, Mohan B, Kurmi P, Kumar SR, Sawardekar VM, Mishra A, Murthy LS, Arya VV, Sonawane AR, Soni PN, Gofne SK, Karnawat SR, Rajurkar MN, Patel PM, Lakhwani LK, Mehta SC, Joglekar SJ. Fixed-Dose Combination of Dapagliflozin + Sitagliptin + Metformin in Patients with Type 2 Diabetes Poorly Controlled with Metformin: Phase 3, Randomized Comparison with Dual Combinations. Adv Ther. 2023 Jul;40(7):3227-3246. doi: 10.1007/s12325-023-02523-z. Epub 2023 May 31. PMID: 37258803.

  • * Cuatrecasas G, De Cabo F, Coves MJ, Patrascioiu I, Aguilar G, Cuatrecasas G, March S, Calbo M, Rossell O, Balfegó M, Benito C, Di Gregorio S, Garcia Lorda P, Muñoz E. Dapagliflozin added to metformin reduces perirenal fat layer in type 2 diabetic patients with obesity. Sci Rep. 2024 May 11;14(1):10832. doi: 10.1038/s41598-024-61590-6. Epub 2024 May 11. PMID: 38734755; PMCID: PMC11088615.

  • * Triplitt C, Cersosimo E, Alatrach M, Adams J, Hansis-Diarte A, Baskoy G, Gastaldelli A, Chavez-Velazquez A, DeFronzo RA. Changes in β-Cell Function and Insulin Sensitivity During Treatment With Dapagliflozin Alone or in Combination With Exenatide in Type 2 Diabetes. Diabetes Care. 2025 Sep 1;48(9):1545-1552. doi: 10.2337/dc25-0490. PMID: 40627548; PMCID: PMC12368385.

  • * Attia N, Al Noaim K, Mustafa M, Al Fifi SH, Al Alwan I, Thalange N, Babiker A. The Use of Dapagliflozin in the Treatment of Children With Severe Insulin Resistance. Pediatr Diabetes. 2025;2025:6859764. doi: 10.1155/pedi/6859764. Epub 2025 Dec 20. PMID: 41424588; PMCID: PMC12717530.

  • * Chee YJ, Acharyya S, Liew H, Seow CJ, Goh LL, Boehm BO, Dalan R. First-Line Dapagliflozin, Metformin, or Combination Therapy in Type 2 Diabetes: Vascular and Molecular Outcomes of a Randomised Controlled Trial. Diabetes Obes Metab. 2026 Sep;28(9):8568-8580. doi: 10.1111/dom.71056. Epub 2026 Jul 3. PMID: 42396722; PMCID: PMC13449050.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.